https://orcid.org/0000-0002-9198-9445
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
"Modern prostate cancer diagnostics reduce overdiagnosis – will they open up for population-based screening?." Scandinavian Journal of Urology, 55(6), pp. 491–492
Disclosure statement
Hans Lilja is named on patents on assays for intact PSA and patents on a statistical method to detect prostate cancer (4KScore test) licensed to Arctic Partners that is sublicensed to and commercialized by OPKO Health. Hans Lilja receives royalties from sales of this test, and has stock in OPKO Health, Arctic Partners, Diaprost AB, and Acousort AB. No potential conflict of interest was reported by Ola Bratt.
Additional information
Funding
This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], SPORE grant in Prostate Cancer [P50 CA092629], R01 CA244948, the Swedish Cancer Society/Cancerfonden (20 1354PjF), and General Hospital in Malmö Foundation for Combating Cancer.